Takeda Signs an Exclusive License and Research Agreement with MD Anderson for CAR NK Cell Therapies

Takeda’s Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada’s Approval for the Treatment of Patients with Attention Deficit/Hyperactivity Disorder Aged≥ 6yrs.


  • Takeda to get rights to develop and commercialize up to four programs including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and will also have rights to access MD Anderson’s CAR NK platform
  • MD Anderson to get upfront payment and is eligible to receive development and commercial milestones for each target and royalties on sales of any CAR NK product. The companies will conduct a research collaboration to advance these CAR NK programs
  • Additionally, Takeda and its partners are evaluating multiple gamma delta CAR-Ts, induced pluripotent stem cell-derived CAR-Ts, CAR-Ts targeting solid tumors, and other next-generation approaches for the improvement of safety, efficacy, and accessibility of first-generation CAR T-cell therapies while plans to advance 5 oncology cell therapies to the clinic by the end of FY20
  • CAR NK-cell platform involves isolation of NK cells from umbilical cord blood expressing CARs against specified cancer targets while CD19 CAR NK-cell therapy is been evaluated in P-I/IIa treating patients with relapsed and refractory B-cell malignances with expected enrollment in 2021

Click here to­ read full press release/ article | Ref: Takeda | Image: Behance